-
death protein 1 (PD-1)
monoclonal antibody that acts as a
checkpoint inhibitor. In 2018,
toripalimab was
approved in
China for the
treatment of unresectable...
-
programmed cell
death ligand 1 (PD-L1).
Durvalumab is an
immune checkpoint inhibitor drug. It was
approved in for
medical use in the
United States in May 2017...
-
blocks PD-1. It is a type of
immunotherapy and
works as a
checkpoint inhibitor,
blocking a
signal that
prevents activation of T
cells from attacking...
- byp****ing
immune surveillance. In
mouse tumor models, it was
shown that
inhibiting PD-1
activity decreased tumor growth. In the
Garnet Trial, dostarlimab...
-
brand name Keytruda, is a
humanized antibody, more
specifically a PD-1
inhibitor, used in
cancer immunotherapy that
treats melanoma, lung cancer, head...
- v t e PD-1 and PD-L1
inhibitors PD-1
inhibitorsTooltip Programmed cell
death protein 1
Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab...
- PMID 32306208. S2CID 215804809. New PD-1
Inhibitor OK'd for
Cutaneous SCC -
Sixth PD-1/PD-L1
checkpoint inhibitor approved by
agency 2018 "FDA
approves cemiplimab-rwlc...
-
reduced appetite, diarrhea, and cough.
Atezolizumab was the
first PD-L1
inhibitor approved by the U.S. for
bladder cancer. Food and Drug Administration...
- IgG1 that
binds to the
programmed death-ligand 1 (PD-L1) and
therefore inhibits binding to its
receptor programmed cell
death 1 (PD-1).
Formation of a...
-
Monoamine oxidase inhibitors (MAOIs) are a
class of
drugs that
inhibit the
activity of one or both
monoamine oxidase enzymes:
monoamine oxidase A (MAO-A)...
